文献速递结核与非结核分枝杆菌艾滋病与性传播感染

估计耐多药结核病患者治疗成功后复发风险:合并与不合并人类免疫缺陷病毒者中死亡与失访假设的影响

Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up.
PubMed 文献 · Clin Infect Dis · 2024-01-01

研究分析2015至2018年16个国家1991例成功完成含贝达喹啉和/或德拉马尼的较长MDR/RR-TB方案的患者,采用5种处理治疗后死亡的方法估计6个月复发风险。总体复发风险低,约为7.4/1000至7.6/1000,与HIV状态的关联因复发事件少而不确定。

要点

  • 1991例成功完成含贝达喹啉和/或德拉马尼的较长MDR/RR-TB方案患者中,6个月结核复发风险约为7.4/1000至7.6/1000。
  • 将死亡作为非复发处理时复发风险为7.4/1000(95%可信区间3.3-12.8),将死亡删失并应用逆概率加权时为7.6/1000(3.3-13.0)。
  • 与HIV状态的关联因复发事件少而不确定,不同假设下相对风险的方向和幅度不一。

核心结论

  • 估计的6个月结核复发风险低,与HIV状态的关联因复发事件少而不确定。
  • 对死亡做出明确假设并对缺失随访数据进行适当调整,将改进治疗后复发的估计。

研究设计与样本

  • 分析2015至2018年16个国家1991例成功完成含贝达喹啉和/或德拉马尼的较长MDR/RR-TB方案的患者数据。
  • 使用5种处理治疗后死亡的方法,总体及按HIV状态估计6个月治疗后结核复发风险。
  • 使用逆概率加权处理缺失随访患者,并研究未应用逆概率加权而排除这些患者可能带来的偏倚影响。

主要发现

  • 将死亡作为非复发处理时,估计的结核复发风险为7.4/1000(95%可信区间3.3-12.8)。
  • 将死亡删失并应用逆概率加权处理排除的死亡时,估计的结核复发风险为7.6/1000(95%可信区间3.3-13.0)。
  • 复合复发结局的估计风险分别为:复发或任何死亡25.5/1000(95%可信区间15.3-38.1),复发或原因不明或结核相关死亡11.7/1000(6.4-18.2),复发或结核相关死亡8.6/1000(4.1-14.4)。
  • HIV状态的相应相对风险在不同假设下方向和幅度不一。
  • 未应用逆概率加权而排除缺失随访患者对估计值影响小。

局限性

  • 与HIV状态的关联因复发事件少而不确定。
  • 未应用逆概率加权而排除缺失随访患者可能带来偏倚,但本研究中影响小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). However, such analyses are complicated when some patients die or become lost during post-treatment follow-up. METHODS: We analyzed data on 1991 patients who successfully completed a longer MDR/RR-TB regimen containing bedaquiline and/or delamanid between 2015 and 2018 in 16 countries. Using 5 approaches for handling post-treatment deaths, we estimated 6-month post-treatment TB recurrence risk overall and by HIV status. We used inverse-probability weighting to account for patients with missing follow-up and investigated the impact of potential bias from excluding these patients without applying inverse-probability weights. RESULTS: The estimated TB recurrence risk was 7.4/1000 (95% credible interval: 3.3-12.8) when deaths were handled as non-recurrences and 7.6/1000 (3.3-13.0) when deaths were censored and inverse-probability weights were applied to account for the excluded deaths. The estimated risks of composite recurrence outcomes were 25.5 (15.3-38.1), 11.7 (6.4-18.2), and 8.6 (4.1-14.4) per 1000 for recurrence or (1) any death, (2) death with unknown or TB-related cause, or (3) TB-related death, respectively. Corresponding relative risks for HIV status varied in direction and magnitude. Exclusion of patients with missing follow-up without inverse-probability weighting had a small impact on estimates. CONCLUSIONS: The estimated 6-month TB recurrence risk was low, and the association with HIV status was inconclusive due to few recurrence events. Estimation of post-treatment recurrence will be enhanced by explicit assumptions about deaths and appropriate adjustment for missing follow-up data.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sauer SM, Mitnick CD, Khan U, et al. Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up. Clin Infect Dis. 2024. PMID: 37773767. doi:10.1093/cid/ciad589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。